Vorasidenib

About

Therapy type: Targeted therapy

Therapy strategy: IDH1/2 inhibition

Mappings

NCI Thesaurus: Vorasidenib (ncit:C152914)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) IDH1 p.R132C Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132G Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132H Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132L Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132S Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172K Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172M Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172G Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172S Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172W Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132C Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132G Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132H Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132L Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132S Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172K Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172M Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172G Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172S Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172W Oligodendroglioma Vorasidenib